Company Cash Volume: Oramed Pharmaceuticals (ORMP)

Public company logo of Oramed Pharmaceuticals (ORMP)

A strategic pivot toward patent licensing following the failure of its primary project defines the current development trajectory of Oramed Pharmaceuticals (ORMP). This cash liquidity chart confirms the trend, with the value stabilizing at 0.05. Growth potential is based on diabetic demand for oral insulin; however, global logistical risks and trade barriers create additional complexities for the company's expansion.

oramed.com - ORMP Company Cash Balance (period 07/04/2022 - 11/21/2026)

Financial and market metric breakdowns for Oramed Pharmaceuticals (ORMP)

- company stock exchange capitalization indicators:
Comprehensive company analysis:ORMP Oramed Pharmaceuticals
Brand item of Oramed Pharma

Oramed Pharmaceuticals (ORMP) minimizes R&D risks by developing innovative oral drug formulations for the diabetes market. By analyzing the company's cash liquidity, an investor assesses the amount of mobile capital that serves as a defensive buffer during periods of volatility; however, an excessive cash reserve may lead to inflationary depreciation, which is critical for evaluating the fundamental stability of the business.

Direct competitors

Company Cash Funds Haleon (HLN)|Company Cash Volume Kenvue Inc. (KVUE)|Company Cash Volume VRNA (veronapharma.com)|Company Cash Balance MENS|LGND: Company Cash on Hand|Company Cash Balance AMRX (Amneal Corp)|PRGO (Perrigo Company plc) - Company Cash on Hand|Alvotech - Company Cash Balance|Company Cash on Hand LQDA|Galapagos Genomics (GLPG) - Company Liquid Assets|Company Cash Volume ANIP|Company Cash on Hand Afrezza MNKD|Company Cash Funds Amphastar AMPH|Company Liquid Assets Pacira BioSciences (PCRX)|ARS Corp - Company Cash Volume|TBPH: Company Cash Funds|AQST: Company Cash Volume|SCPH - Company Liquid Assets|TECX (Tectonic) - Company Cash Volume|Company Cash Reserve Tonix Pharmaceuticals Holding Corp. TNXP|Company Cash Funds SXT Pharmaceuticals (SXTC)|Company Cash Volume Eupraxia Pharmaceuticals Inc. (EPRX)|Company Cash Funds BioHarvest Sciences BHST|EXOZ (Invizyne) - Company Total Cash Volume|ENTX - Company Cash Funds|Company Liquid Assets MindWalk Holdings HYFT|ABVC: Company Cash Volume|Company Cash on Hand Cumberland Pharmaceuticals Inc.|Company Cash Funds Quantum BioPharma Limited|FGEN: Company Cash Balance|Company Cash Volume TELO|Rani Therapeutics Holdings, Inc. - Company Cash and Cash Equivalents|Company Cash Funds Synergy CHC Corp. SNYR|Company Cash Balance RLYB|LEXX: Company Cash on Hand|Company Cash Balance PULM (Pulmatrix Corporation)|Pheton Holdings Limited (PTHL) - Company Cash Funds|Company Cash on Hand Aptorum|Company Cash on Hand LYRA|Impact BioMedical Inc - Company Total Cash Volume|Company Cash Volume TNFA|YCBD - Company Cash Reserve|PainReform Ltd. - Company Cash on Hand|CYTO (Auris Medical) - Company Total Cash Volume|LIPO - Company Cash Funds|Company Cash Balance OPTN (OptiNose)|PIRS: Company Cash Volume|Procaps Group S.A. (PROC) - Company Cash Volume|PTPI (Petros Pharma) - Company Cash Volume|QLI: Company Cash Balance|Company Cash Volume SLRN|TFFP (TFF Pharmaceuticals Inc.) - Company Cash Balance